Lawrence Steinman - Jun 21, 2022 Form 4 Insider Report for Pasithea Therapeutics Corp. (KTTA)

Role: Director
Signature: /s/ Larry Steinman
Stock symbol: KTTA
Transactions as of: Jun 21, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/22/2022, 04:30 PM
Previous filing: Jun 17, 2022
Next filing: Jun 23, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KTTA	Common Stock	Award	$0	+652K	+108.7%	$0.00	1.25M	Jun 21, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KTTA	Stock option (to acquire common stock)	Award	$0	+100K		$0.00	100K	Aug 2, 2021	Common Stock	600K	$6.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock of the Issuer issued in connection with the acquisition of the ALPHA-5 Integrin, LLC on June 21, 2022.
F2	The Reporting Person was granted 100,000 stock options. The stock options have a ten-year term and vest over two years, subject to reporting person remaining employed and in good standing, one-half vesting on the first anniversary of the grant date, and the remainder vesting on the second anniversary of the grant date.